Estimating incremental cost-effectiveness ratios and their confidence intervals with differentially censored data. Academic Article

abstract

• With medical costs escalating over recent years, cost analysis is being conducted more and more to assess economic impact of new treatment options. An incremental cost-effectiveness ratio (ICER) is a measure that assesses the additional cost for a new treatment for each additional unit of effectiveness, such as saving 1 year of life. In this article, we consider cost-effectiveness analysis for new treatments evaluated in a randomized clinical trial setting with staggered entries. In particular, the censoring times are different for cost and survival data. We propose a method for estimating the ICER and obtaining its confidence interval when differential censoring exists. Simulation experiments are conducted to evaluate our proposed method. We also apply our methods to a clinical trial example comparing the cost-effectiveness of implanted defibrillators with conventional therapy for individuals with reduced left ventricular function after myocardial infarction.

authors

• Zhao, Hongwei

published proceedings

• Biometrics

author list (cited authors)

• Wang, H., & Zhao, H.

citation count

• 8

complete list of authors

• Wang, Hongkun||Zhao, Hongwei

publication date

• June 2006

publisher

• Wiley  Publisher

published in

• Biometrics  Journal

keywords

• Biometry
• Confidence Intervals
• Cost-benefit Analysis
• Data Interpretation, Statistical
• Defibrillators, Implantable
• Humans
• Models, Statistical
• Myocardial Infarction
• Randomized Controlled Trials As Topic
• Survival Analysis
• Ventricular Dysfunction, Left

PubMed Central ID

• 16918922

Digital Object Identifier (DOI)

• 10.1111/j.1541-0420.2005.00502.x

start page

• 570

end page

• 575

volume

• 62

issue

• 2

URL

• http%3A%2F%2Fdx.doi.org%2F10.1111%2Fj.1541-0420.2005.00502.x

user-defined tag

• 3 Good Health and Well-Being